New Millennium Group LLC Has $33,000 Stock Position in AstraZeneca PLC $AZN

New Millennium Group LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 57.7% in the second quarter, according to its most recent filing with the SEC. The firm owned 479 shares of the company’s stock after selling 654 shares during the period. New Millennium Group LLC’s holdings in AstraZeneca were worth $33,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in AZN. NewSquare Capital LLC increased its position in shares of AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock worth $25,000 after purchasing an additional 218 shares in the last quarter. Larson Financial Group LLC grew its position in shares of AstraZeneca by 297.9% during the 1st quarter. Larson Financial Group LLC now owns 386 shares of the company’s stock worth $28,000 after buying an additional 289 shares during the period. Richardson Financial Services Inc. grew its position in shares of AstraZeneca by 59.8% during the 2nd quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock worth $28,000 after buying an additional 149 shares during the period. Costello Asset Management INC acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, Maseco LLP acquired a new stake in shares of AstraZeneca during the 2nd quarter worth approximately $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of several recent analyst reports. Berenberg Bank set a $97.00 price objective on shares of AstraZeneca in a research note on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group started coverage on shares of AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

AstraZeneca Price Performance

Shares of AZN opened at $82.03 on Wednesday. The company has a market cap of $254.41 billion, a price-to-earnings ratio of 30.84, a PEG ratio of 1.52 and a beta of 0.36. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $86.57. The company’s fifty day simple moving average is $81.21 and its 200 day simple moving average is $75.28. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.